High mannose proteins and methods of making high mannose proteins
CA 2767473 C · Owner: Shire Human Genetic Therapies, Inc. · Inventors: Kinoshita, Carol M.; Francis Daniel, Peter; Borowski, Marianne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB) and allowing production of GCB having a precursor oligosaccharide under conditions which prevent the removal of at least one mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB to thereby produce an hmGCB preparation. Preferably the condition which prevents the removal of at least one mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB preparation and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 17, 2001 and granted September 13, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 17, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 17, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.